i believe this is not only possible, but will happen sooner rather than later because of advancing capabilities in software, machine learning, and collaboration. we simply need the right people providing capital and launching these biotechs.

re patents, the key is to drive down costs for research and testing. research seems like the low-hanging fruit, comparatively speaking, but it's unclear how to reduce the costs of clinical trials in an uncontroversial way.